Private Capital Advisors Inc. grew its position in shares of ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) by 294.1% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 39,397 shares of the exchange traded fund’s stock after purchasing an additional 29,401 shares during the quarter. Private Capital Advisors Inc. owned about 0.52% of ProShares Ultra Nasdaq Biotechnology ETF worth $2,209,000 as of its most recent SEC filing.
Shares of ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) opened at $61.53 on Friday. ProShares Ultra Nasdaq Biotechnology ETF has a 52-week low of $43.67 and a 52-week high of $69.62.
COPYRIGHT VIOLATION WARNING: “ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) Stake Raised by Private Capital Advisors Inc.” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/04/proshares-ultra-nasdaq-biotechnology-etf-bib-shares-bought-by-private-capital-advisors-inc.html.
About ProShares Ultra Nasdaq Biotechnology ETF
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.
Receive News & Ratings for ProShares Ultra Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares Ultra Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.